Study Design. The ability of lentivirus vector (LV) survivintransforming growth factor beta 3 (TGFB3)-tissue inhibitor of metalloproteinases 1 (TIMP1) on slowing disc degeneration was evaluated by an animal experiment. Objective. The aim of the study was to investigate the effect of LV survivin-TGFB3-TIMP1 on slowing disc degeneration in an in vivo rabbit model. Summary of Background Data. Cell apoptosis, increase of catabolic activity, and decrease of anabolic activity were the mechanisms of disc degeneration. Meanwhile, survivin, TGFB3, and TIMP1 can influence above process, respectively. However, there were no researches conducted to evaluate the effect of an LV containing all three proteins (referred to as LV-survivin-TGFB3-TIMP1) on slowing disc degeneration in vivo. Methods. Twenty skeletally mature female New Zealand White rabbits were randomly divided into four groups: nonpunctured sham surgical group (group A, n ¼ 5), punctured blank control group (group B, n ¼ 5), punctured empty vector control group (group C, n ¼ 5), and the treatment group (group D, n ¼ 5). Computed tomography-guided puncture was performed at the L3-L4 and L4-L5 discs, in accordance with a previously validated rabbit annulotomy model for intervertebral disc degeneration.
A pproximately 80% of the aging population suffer from low back pain at some point in their lives. [1] [2] [3] Back pain associated with intervertebral disc degeneration (IDD) dramatically affects quality of life and work productivity, and significantly impacts health care spending. 4 Disc degeneration is associated with spinal stenosis, facet hypertrophy, herniation, and other morbidities. Current first-line treatments include activity modification, analgesic and anti-inflammatory medications, and physical therapy, although these only relieve symptoms provisionally and patients may eventually become surgical Alternative, less invasive, treatment paradigms, such as gene therapy, are being developed to slow or reverse the degenerative process within IDD.
Developing approaches to stimulating regeneration of disc tissue or slowing the degeneration progression requires an understanding of the causes of the degeneration. Mechanisms that may contribute to the degenerative change in a disc include a decreasing concentration of cells resulting from necrosis and apoptosis, 7 an increase in catabolic activity, and a decrease in anabolic activity. 8 These mechanisms provide direction and fundamental information for gene therapy.
Survivin protein, a baculoviral inhibitor of apoptosis, plays an important role in the regulation of mitosis progression and apoptosis inhibition. 9 In osteoarthritis and rheumatoid arthritis, survivin stimulates chondrocytes proliferation and inhibits apoptosis. 10, 11 Furthermore, preliminary studies have indicated that survivin is expressed in fetal disc tissue, and that there is a differential expression of survivin between degenerated nucleus pulposus (NP) tissue and relatively normal NP tissue. 12, 13 Transforming growth factor beta 3 protein (TGFB3), one of the members of the TGF-beta superfamily, regulates critical processes such as cells proliferation and the expression of extracellular matrix (ECM) genes. 14 The present study demonstrates that TGFB3 enhances the survival and viability of intervertebral disc (IVD) cells in organ culture, and allows for continued expression of aggrecan and collagen type II in culture. 15 Tissue inhibitor of metalloproteinases 1 (TIMP1) is an anticatabolic growth factor that prevents matrix metalloproteinase-3 from enzymatically cleaving proteoglycans in the IVD. 16 Sai JiaMing et al 17 injected adenovirus-transduced TGFB3 into NP cells in vitro, and demonstrated that the expression of aggrecan and collagen type II were increased. Wallach et al 18 used TIMP1 for IVD cell transfection and showed the expression of aggrecan was increased in transfected cells. In our previous research, we demonstrated that survivin is re-expressed in disc degeneration disease and is required for degenerated NP cell proliferation and antiapoptosis in vitro. 19 Because prior in vitro studies for treatment the IDD have yielded encouraging results and have proved survivin, Tgfb3, and Timp1 as target genes for gene therapy. Because these three genes can influence disc degeneration from cell apoptosis, catabolic activity, and anabolic activity of ECM, respectively, the cotransfection combination shows promise for the treatment of IDD. However, there were no researches conducted about the effect of a lentivirus vector (LV) containing all three proteins (referred to as LV-survivin-TGFB3-TIMP1) on slowing disc degeneration in vivo.
This study investigated the utility of gene therapy in improving IDD by administering LV-survivin-TGFB3-TIMP1 into disc cells. We used this validated IDD model to determine whether treatment with LV-survivin-TGFB3-TIMP1 can ameliorate the course of disc degeneration. The results provide fundamental information for gene therapy to decelerate IDD in future clinical application.
MATERIALS AND METHODS

Materials
Twenty skeletally mature female New Zealand White rabbits (female, 3-months-old, weighing 2-2.5 kg) were randomly divided into four groups: a nonpunctured sham surgical group (no degeneration and no injection, group A, n ¼ 5), a punctured blank control group (degeneration and placebo injection, group B, n ¼ 5), a punctured negative control group (degeneration and an empty LV injection, group C, n ¼ 5), and a treatment group (degeneration and LV-survivin-TGFB3-TIMP1 injection, group D, n ¼ 5) (Table 1) . LV-survivin-TGFB3-TIMP1 and empty LV were purchased from Shanghai Genechem Co. Ltd (Shanghai, China). The titers of LV-survivin-TGFB3-TIMP1 and empty LV were 2 Â 10 8 and 1 Â 10 9 TU/ml, respectively. The Animal Care and Use Committee of the Affiliated Hospital of Qingdao University, Shandong, China, approved all animal experimental protocols, which followed the principles expressed in the National Institute of Health Guide.
Puncture Surgery
Computed tomography (CT)-guided percutaneous needle puncture technology was used to establish this model. 20 Magnetic resonance imaging (MRI) and histology showed changes that resembled the hallmarks of human disc degeneration. In brief, rabbits were anesthetized with Su Mian Xin II (0.15 ml/kg intramuscularly) and atropine sulfate (0.05 mg/ kg intramuscularly), the position of the target discs (L3-L4 and L4-/L5) were identified using CT, and then a 16-gauge needle was inserted toward the center of the disc, with CT guidance. The needle pinpoint was confirmed to be positioned in the disc center by CT ( Figure 1A -C). In the sham group, the 16-gauge needle only punctured the muscle along the same needle path. Postoperatively, the rabbits were housed in individual cages and injected intramuscularly with penicillin at 80 Â 10 5 U to prevent infection.
Injection Surgery
At 3 weeks postpuncture surgery, groups B, C, and D were injected with equivalent phosphate buffer saline, empty LV, and LV-survivin-TGFB3-TIMP1, respectively, using CTguided percutaneous needle injection technology (Table 1) . This time point was selected because it is the earliest that MRI changes of degeneration have been detected with this model.
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A 100 ml microinjector (Hamilton, Bonaduz, Switzerland) was used for therapeutic injections into the center of the NP.
Magnetic Resonance Imaging
MRIs were obtained at time point 0 (before puncture), 3 weeks postpuncture (before injection), and 12 weeks postpuncture (before death) for all rabbits. A 3-T standard human knee coil was used to obtain T2-weighted images [repetition time ¼ 2120 ms, echo time (TE) ¼ 113 ms, slice thickness ¼ 0.6 mm]. The rabbits were anesthetized and placed in the knee coil in the supine position. A previously validated automated segmentation method was used, in which a computer program identified the signal isoline intensity of the disc and adjacent vertebrae and generated a contour map of the NP. 21 The largest closed area between two adjacent vertebrae represents the NP and was selected as the region of interest ( Figure 2 ). The MRI index is the sum of pixel area multiplied by pixel intensity for all identified NP tissue.
Histologic Processing
All rabbits were sacrificed 12 weeks after the initial puncture surgery, after the final MRI scan. Immediately after death, spines were dissected out en bloc. The L3-L4 discs (n ¼ 5 per group) were prepared for histology. Two discs from each group were fixed and then dehydrated using a histology tissue processor and embedded in paraffin. Next, the discs were sectioned at a thickness of 5 mm in the coronal plane. The sections were stained with H&E (Beijing Leagene Biotechnology Co. Ltd, Beijing, China). The other discs were embedded in Tissue-Tek (Sakura, CA) and then sectioned at a thickness of 5 mm in the coronal plane in freezing microtome (Leica CM1950, Leica Biosystems, Wetzlar, Germany). The sections were stained for immunofluorescence using collagen type II and aggrecan antibodies (ab34712 and ab36861; Abcam, Cambridge, MA) and were imaged using an OLYMPUS BX51 microscope (OLYMPUS, Tokyo, Japan). Expression of Survivin, Tgfb3, and Timp1 Genes and Aggrecan and Collagen Type II Protein Content Three L4-L5 discs from each group (n ¼ 5 per group) were prepared for quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot analysis. mRNA was extracted from NP tissue using TRIzol (Invitrogen, San Diego, CA) and the absorbance at 260 and 280 nm was measured for quantification and quality control. A total of 1 mg mRNA was reversely transcribed to cDNA using PrimeScript RT reagent (catalogue number: DRR037A; Takara Bio Inc., Shiga, Japan), and the reaction product was treated with RNAse-free DNase I. PCR was conducted using the cycling conditions (LightCycler 480 Instrument II) as per manufacturer's instructions. Primers were designed and purchased from Shanghai Sangon Biotech Co. Ltd (Shanghai, China) ( Table 2 ). Another specific primer pair for human glyceraldehyde-3-phosphate dehydrogenase was used as an internal control. In each experiment, samples were analyzed in duplicate. The normalized target gene expression was determined through comparative Ct method (DDCt method).
NP tissues were washed with ice-cold phosphate buffer saline, weighed, and grounded by using mortar and pestle. Lysis was performed on ice for 45 minutes using 200 ml of radioimmunoprecipitation assay buffer with 2 ml of phenylmethanesulfonylfluoride for every 100 mg of tissue. After, the lysis solution was centrifuged at 12,000 r/min and 48C for 20 minutes. For the Western blot analysis of survivin, glyceraldehyde-3-phosphate dehydrogenase was used as an internal control, and proteins were resolved through sodium dodecyl sulfate-polyacrylamide gel electrophoresis by using a 10% gel, prior to transferring onto Immobilon P membranes (Millipore, Bedford, MA). The membranes were blocked with 5% fat-free dried milk and probed with a monoclonal rabbit antibody (antibodies: ab34712 and ab36861; Abcam). After incubation with horseradish peroxidase-conjugated secondary antibodies, the positive bands were visualized using chemiluminescence (Pierce, Rockford, IL).
Caspase-3 Activity Assay
The remaining L4-L5 discs were prepared for caspase-3 activity. NP cells were cultured as described in a previous study. 22 In brief, the NP tissue was cut into small pieces ($1 mm 2 ) and then digested with 0.25% trypsinase (HyClone) at 378C under gentle agitation for 20 minutes. Then, 0.5% collagenase type II (MP Biomedicals, LLC, CA) was used at 378C for approximately 4 hours. The cells were transferred to a 12.5 cm 2 culture flask at a density of 10 5 cells/cm 2 . The cells were cultured in a CO 2 incubator (Sanyo Electric Co. Ltd, Osaka, Japan) at 378C with humidity, and grown in DMEM-F12 containing 15% fetal calf serum. The experiments were analyzed in duplicate. The caspase-3 activity was measured using the Caspase-3 Colorimetric Assay Kit (BioVision Inc., CA). The NP cells were counted and pelleted at 1.5 Â 10 6 cells. The cells were then resuspended in cell lysis buffer, and 50 ml of 2 Â reaction buffer (containing 10 mM DTT) and 5 ml of DEVE-pNA were added. The samples were incubated for 90 minutes at 378C and their optical densities were read at 405 nm using a microtiter plate reader (Sunrise, Tecan Group Ltd, Mä nnedorf, Switzerland).
Statistical Analysis
All values were presented as mean AE SEM. Student t test and one-way ANOVA with a post hoc Fisher least significant difference test were applied to reveal the statistical significance of the differences. Statistical analyses were performed using SPSS software for Windows (Version 19; SPSS Inc., Chicago, IL).
RESULTS
Imaging
The T2-weighted midsagittal MRI scans of group A did not show any evidence of disc degeneration. NP images from groups B and C were darkened and decreased in area from 0 to 12 weeks, consistent with degeneration. Group D demonstrated less qualitative evidence of degeneration than groups B and C: treated NPs did not darken and decrease in area as much as the punctured discs. The morphology of the group A discs showed an abundance of water and ECM. Discs from groups B and C decreased in amount of both water and ECM, and were the morphology of fibrosis different, consistent with degeneration; however, the amounts of water and ECM in group D were between group A and groups B and C ( Figure 3A-D) . 
Immunofluorescence of Collagen Type II and Aggrecan
The expression and distribution were analyzed using immunofluorescence. In group A, the distribution of collagen type II and aggrecan were uniform and compact. In groups B and C, the proteins decreased and appeared looser. However, group D was between group A and groups B and C ( Figure 6A-D) .
Caspase-3 Activity Reflected Apoptosis of NP Cells
The caspase-3 activity of NP cells was assayed. Under the relatively normal culture conditions, group D did not show significantly altered caspase-3 activity compared with groups B and C (P ¼ 0.47 and P ¼ 0.16, respectively). When exposed to ischemia in vitro (1% oxygen, glucose deprivation), the caspase-3 activity of all groups increased compared to normal culture conditions (P ¼ 0.00). However, caspase-3 activity remained significantly decreased overall for group D (group D þ in vitro ischemia vs. group B þ in 
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Survivin-TGFB3-TIMP1 Gene Therapy Via Lentivirus Vector Yue et al vitro ischemia and group C þ in vitro ischemia: P ¼ 0.01 and P ¼ 0.03, respectively) ( Figure 7 ).
Histological Staining
The histological analysis of NP tissues was performed using H&E staining. Normal discs from group A showed an entirely normal tissue construction and a clear distinction between the NP and AF; however, in degeneration and injection groups, the distinction was lost in correlation with the degree of degeneration (Figure 8 40Â) , and the fibrosis was shown in degeneration and injection groups (Figure 8  200Â) . Meanwhile, the NP tissue of group A showed no fibrosis. Under the highest magnification (Figure 8 400Â) , the number of NP cells in injection groups showed a significant decrease compared with normal group and a significant increase compared with degeneration group. 
DISCUSSION
This study has shown that LV-survivin-TGFB3-TIMP1 injection into the IVD could slow the process of IDD in vivo. Results from MRI, histology, gene expression, protein content, and apoptosis analyses all demonstrated a slowing of the course of injury-induced degeneration. The degeneration model was established by using CTguided percutaneous needle puncture technology. Although an injury model for disc degeneration does not truly reflect the complex biochemical cascade of human degenerative disc disease, it does show that LV-survivin-TGFB3-TIMP1 is a possible treatment method to ameliorate the process of injury-induced degeneration. Similarly, injection surgery was accomplished with CT guidance; however, we used a microinjector with a needle small enough so that it would not exacerbate further degeneration. 23 Furthermore, 3 weeks after the puncture, there was a change in NP visible by MRI, and the degeneration was in an early phase. In the phase, the cellular state might be able to mount a healing response for LV injection, so this time point was chosen for the LV injection. 24 Our current study quantified the amount of IDD by manually segmenting the rabbit NP and calculating the MRI index; however, accurate identification of the NP is crucial to properly and objectively assess the IVD. A contour segmentation method can semiautomatically segment the NP on the basis of the difference in intensity between the NP (bright) and AF (dark) structures. By generating an isoline 
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Survivin-TGFB3-TIMP1 Gene Therapy Via Lentivirus Vector Yue et al intensity image of the IVD from the T2-WI, the user can easily distinguish the two structures and select the NP. 18 For eliminating intensity error due to different scanning times, the relative MRI index was calculated (the ratio of interest discs MRI index and L2-L3 index). Furthermore, it has been demonstrated that MRI-detected degeneration induced by the puncture model correlated with disc water and proteoglycan content. 25 In this study, the group A relative MRI index did not change over time; groups B, C, and D decreased similarly 3 weeks before LV injection; at 12 weeks, the index showed a significant difference between group D and groups B and C. These results showed that LV-survivin-TGFB3-TIMP1 injection was helpful for preservation of IVD. However, the preservation was not notable, and it is possible that the 12-week course of this study may have been insufficient to demonstrate the full therapeutic effect in the degenerative cascade.
The gene expression of survivin, Tgfb3, and Timp1 in NP tissues of different groups was investigated in this study. In group D, the expression of these three genes was significantly increased compared with groups B and C. These results indicated that there was a stable expression of target genes in NP cells after in vivo LV-survivin-TGFB3-TIMP1 injection into rabbits. Thus, based on the effect and function of these three genes, a decrease in apoptosis of IVD cells, increase in content of aggrecan and collagen type II, and improved structure of collagen type II and aggrecan compared to punctured control groups were detected. This finding suggests that LV-survivin-TGFB3-TIMP1 injected may have a future role in the treatment of disc disease and therefore warrants further investigation. Caspase-3 activity was analyzed by caspase-3 activity assay and no alteration between the caspase-3 activities of groups D, B, and C was found in the unstressed NP cells; however, in in vitro ischemia cultures (1% oxygen, glucose deprivation), the caspase-3 activity of the NP cells significantly increased compared with unstressed NP cells, and the increase of group D caspase-3 activity was less than that of groups B and C, the difference being statistically significant. These results were consistent with our previous research, 24 and revealed that ischemia culture condition induced NP cell apoptosis, and that overexpression of survivin may contribute in the reduction of caspase-3 activity for anti-apoptosis function in the degeneration process.
The content of aggrecan and collagen type II were analyzed by Western blot, and a significant increase was observed in group D compared with groups B and C, the difference being statistically significant. Furthermore, the results of immunofluorescence staining were consistent with the Western blot analysis. All results concur that LV injection with target genes can lead to overexpression of aggrecan and collagen type II. Based on the expression and function of Tgfb3 and Timp1, it is likely that the two genes injected into NP cells can play a role in slowing the degeneration process.
To identify relevant structural and compositional changes occurring in the different groups, H&E stains were used to evaluate comprehensive structural features, and changes in composition and cell count in NP tissues of the different groups. Other studies have used H&E staining for histologic evaluation of IVD structure and composition. These results show that the fibrosis of NP tissues was gradually aggravated with degeneration, and that LV injection with survivin, TGFB3, and TIMP1 slowed degeneration.
Although this study shows a number of statistically significant findings, there were limitations. All imaging, gene expression, protein content, apoptosis, and histology results demonstrated that the LV injection with survivin, TGFB3, and TIMP1 had a weak effect on slowing degeneration. It is possible that the expression of the three target genes is not uniform; the expression of TGFB3 was nearly 30 times higher than that of others. Therefore, the balance of genes expression would have strengthened this study. Furthermore, the effect of the different injection doses on slowing degeneration in vivo would be studied.
This study demonstrated for the first time that LVsurvivin-TGFB3-TIMP1 injection could slow disc degeneration. Although these results do not necessarily translate to human degenerative disc disease and the results are preliminary compared to clinical treatment, they provide a potential direction for gene therapy as a treatment for disc degeneration.
Key Points
Survivin-TGFB3-TIMP1 shows weak effect on slowing disc degeneration. Transfection of survivin can influence caspase-3 activity in ischemia condition. The overexpression of TGFb3 and TIMP1 leads to the increase of aggrecan and collagen II. The expression of target genes was imbalanced. The imbalance may be the cause of the weak effect on slowing degeneration.
